Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ETGlobeNewsWire • 02/24/25
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.GlobeNewsWire • 02/21/25
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's EyleaInvestopedia • 02/18/25
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)GlobeNewsWire • 02/18/25
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)GlobeNewsWire • 01/27/25
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to TradeZacks Investment Research • 12/16/24
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024GlobeNewsWire • 11/07/24
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)GlobeNewsWire • 11/04/24
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024GlobeNewsWire • 10/25/24
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®GlobeNewsWire • 10/10/24
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®GlobeNewsWire • 09/25/24
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/26/24
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024GlobeNewsWire • 08/15/24
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)GlobeNewsWire • 08/15/24